Renalytix (LON:RENX) Stock Price Down 26.4% – What’s Next?

Renalytix Plc (LON:RENX)’s stock price traded down 26.4% during trading on Wednesday . The company traded as low as GBX 3.74 and last traded at GBX 4.12. 2,113,685 shares were traded during mid-day trading, an increase of 374% from the average session volume of 445,819 shares. The stock had previously closed at GBX 5.60.

Renalytix Trading Down 21.6%

The company has a current ratio of 0.24, a quick ratio of 2.42 and a debt-to-equity ratio of -72.91. The business has a 50 day moving average price of GBX 6.03 and a 200-day moving average price of GBX 6.95. The firm has a market capitalization of £19.19 million, a PE ratio of -0.63 and a beta of 2.10.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).